These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 20018839)

  • 21. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
    Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopaminergic drugs restore facilitatory premotor-motor interactions in Parkinson disease.
    Mir P; Matsunaga K; Gilio F; Quinn NP; Siebner HR; Rothwell JC
    Neurology; 2005 Jun; 64(11):1906-12. PubMed ID: 15955942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of dopamine on semantic activation in Parkinson's disease: evidence from a multipriming task.
    Angwin AJ; Copland DA; Chenery HJ; Murdoch BE; Silburn PA
    Neuropsychology; 2006 May; 20(3):299-306. PubMed ID: 16719623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
    Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
    Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopaminergic modulation of timing control and variability in the gait of Parkinson's disease.
    Almeida QJ; Frank JS; Roy EA; Patla AE; Jog MS
    Mov Disord; 2007 Sep; 22(12):1735-42. PubMed ID: 17557356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of disease progression and L-dopa therapy on the control of reaching-grasping in Parkinson's disease.
    Negrotti A; Secchi C; Gentilucci M
    Neuropsychologia; 2005; 43(3):450-9. PubMed ID: 15707620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different effects of dopaminergic medication on perceptual decision-making in Parkinson's disease as a function of task difficulty and speed-accuracy instructions.
    Huang YT; Georgiev D; Foltynie T; Limousin P; Speekenbrink M; Jahanshahi M
    Neuropsychologia; 2015 Aug; 75():577-87. PubMed ID: 26184442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Basal ganglia, dopamine and temporal processing: performance on three timing tasks on and off medication in Parkinson's disease.
    Jones CR; Malone TJ; Dirnberger G; Edwards M; Jahanshahi M
    Brain Cogn; 2008 Oct; 68(1):30-41. PubMed ID: 18378374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal learning in Parkinson's disease depends on medication status and outcome valence.
    Cools R; Altamirano L; D'Esposito M
    Neuropsychologia; 2006; 44(10):1663-73. PubMed ID: 16730032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
    Winge K; Werdelin LM; Nielsen KK; Stimpel H
    Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequence learning in Parkinson's disease: Focusing on action dynamics and the role of dopaminergic medication.
    Ruitenberg MFL; Duthoo W; Santens P; Seidler RD; Notebaert W; Abrahamse EL
    Neuropsychologia; 2016 Dec; 93(Pt A):30-39. PubMed ID: 27702597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine Replacement Medication Does Not Influence Implicit Learning of a Stepping Task in People With Parkinson's Disease.
    Paul SS; Schaefer SY; Olivier GN; Walter CS; Lohse KR; Dibble LE
    Neurorehabil Neural Repair; 2018 Dec; 32(12):1031-1042. PubMed ID: 30409107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poor dopaminergic response of impaired dexterity in Parkinson's disease: Bradykinesia or limb kinetic apraxia?
    Gebhardt A; Vanbellingen T; Baronti F; Kersten B; Bohlhalter S
    Mov Disord; 2008 Sep; 23(12):1701-6. PubMed ID: 18649388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Risk factors associated with the development of motor complications in Parkinson's disease. A study in a Chilean population].
    Juri-Claveria C; Aguirre-M C; Viviani-G P; Chana-Cuevas P
    Rev Neurol; 2007 Jul 16-31; 45(2):77-80. PubMed ID: 17642046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment.
    Kim HJ; Park SY; Cho YJ; Hong KS; Cho JY; Seo SY; Lee DH; Jeon BS
    J Neurol Sci; 2009 Dec; 287(1-2):200-4. PubMed ID: 19700173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visual-spatial disembedding in Parkinson's disease.
    Crucian GP; Armaghani S; Armaghani A; Foster PS; Burks DW; Skoblar B; Drago V; Heilman KM
    J Clin Exp Neuropsychol; 2010 Feb; 32(2):190-200. PubMed ID: 19484649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The rationale for motor learning in Parkinson's disease.
    Abbruzzese G; Trompetto C; Marinelli L
    Eur J Phys Rehabil Med; 2009 Jun; 45(2):209-14. PubMed ID: 19377414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of aging, Parkinson's disease, and dopaminergic medication on response selection and control.
    Willemssen R; Falkenstein M; Schwarz M; Müller T; Beste C
    Neurobiol Aging; 2011 Feb; 32(2):327-35. PubMed ID: 19269061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease.
    Weinberger M; Mahant N; Hutchison WD; Lozano AM; Moro E; Hodaie M; Lang AE; Dostrovsky JO
    J Neurophysiol; 2006 Dec; 96(6):3248-56. PubMed ID: 17005611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.